Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK3 | Q9NZJ5 | 13/20 | 0.69 |
| ▸ | SRC | P12931 | 5/20 | 0.54 |
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | ABL1 | P00519 | 2/20 | 0.53 |
| ▸ | ABL2 | P42684 | 2/20 | 0.53 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868471 | 0.90 | EIF2AK3 (0.80) | EIF2AK3EIF2AK2 | |
| SCHEMBL2374504 | 0.90 | EIF2AK3 (0.67) | EIF2AK3EIF2AK2 | |
| SCHEMBL869781 | 0.89 | EIF2AK3 (0.68) | EIF2AK3SRCABL1ABL2EIF2AK2 | |
| SCHEMBL868766 | 0.88 | EIF2AK3 (0.74) | EIF2AK3EIF2AK2 | |
| SCHEMBL869430 | 0.85 | EIF2AK3 (0.68) | EIF2AK3SRCEGFRABL1ABL2 | |
| SCHEMBL868231 | 0.85 | EIF2AK3 (0.76) | EIF2AK3EIF2AK2 | |
| SCHEMBL868270 | 0.85 | EIF2AK3 (0.76) | EIF2AK3EIF2AK2 | |
| SCHEMBL24491376 | 0.84 | RIPK1 (0.73) | EIF2AK3SRCEGFRABL1ABL2 | |
| SCHEMBL29651856 | 0.84 | RIPK1 (0.73) | EIF2AK3SRCEGFRABL1ABL2 | |
| SCHEMBL868634 | 0.82 | EIF2AK3 (1.00) | EIF2AK3EIF2AK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2549868-B1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC (US) | 2015-01-07 | — | — | EP | disclosed |
| US-8598156-B2 | Chemical compounds | GLAXOSMITHKLINE LLC (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130018038-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2013-01-17 | — | — | US | disclosed |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | GLAXOSMITHKLINE LLC | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018038-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885SRC 2497/4885EGFR 49/4885 |
| US-20120077828-A1 | CHEMICAL COMPOUNDS | BRCA1, IRS1, IGF1R | EIF2AK3 16/4885SRC 2497/4885EGFR 49/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.